Value of pretransplant albumin-bilirubin score in predicting outcomes after liver transplantation

Table 1 Patient demographics (n = 258)

Patients characteristic	n (%)/mean ± SD/median (IQR)
Demographic feature
Age, yr	47.0 (39.0-56.0)
Male, n (%)	206 (79.8)
Coexisting condition
Smoking, n (%)	78 (30.2)
Drinking, n (%)	44 (17.1)
Hypertension, n (%)	19 (7.4)
Diabetes, n (%)	27 (10.5)
Etiology
Hepatocellular carcinoma, n (%)	87 (33.7)
Viral hepatitis, n (%)	200 (77.5)
Alcoholic cirrhosis, n (%)	8 (3.1)
PBC and AIH, n (%)	21 (8.2)
Other, n (%)	29 (11.2)
Clinical feature
ALBI score	-1.78 (-2.40 - -1.33)
MELD score	15.5 (11.0-23.0)
Child-Pugh grade
A, n (%)	43 (16.7)
B, n (%)	94 (36.4)
C, n (%)	121 (46.9)
Operation time (min)	390.0 (332.5-436.5)
Anhepatic phase (min)	49 (44-58)
Blood loss (mL)	1500 (900-3000)
Total input quantity (mL)	6040 (4810-7810)
Warm ischemia time (min)	9 (8-10)
Cold ischemia time (h)	5 (4-6)

Other etiologies included hepatolenticular degeneration, drug-induced liver injury, upper biliary tract obstruction, acute liver failure, and cryptogenic cirrhosis. SD: Standard deviation; IQR: Inter quartile range; PBC: Primary biliary cirrhosis; AIH: Autoimmune hepatitis; ALBI: Albumin-bilirubin; MELD; Model for end stage liver disease.